US 12,404,346 B2
Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
Manoj Sharma, Hockessin, DE (US); Tatiana Lebedeva, Aston, PA (US); Tatiana Mareeva, Haddonfield, NJ (US); Yuriy Smirnov, Haddonfield, NJ (US); Bogdan Draghici, Newark, DE (US); Zhu Teng, Garnet Valley, PA (US); Yi Feng Zheng, Wilmington, DE (US); Heungyeung Yau, Wilmington, DE (US); Nihmat Morjana, Newark, DE (US); William Bedzyk, Odessa, DE (US); and Allison Dominowski, Middletown, DE (US)
Assigned to Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Appl. No. 17/310,042
Filed by Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
PCT Filed Jan. 30, 2020, PCT No. PCT/US2020/015773
§ 371(c)(1), (2) Date Jul. 13, 2021,
PCT Pub. No. WO2020/160199, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/820,400, filed on Mar. 19, 2019.
Claims priority of provisional application 62/799,399, filed on Jan. 31, 2019.
Prior Publication US 2022/0049018 A1, Feb. 17, 2022
Int. Cl. C07K 16/44 (2006.01); A61K 47/64 (2017.01); A61P 25/36 (2006.01); G01N 33/94 (2006.01)
CPC C07K 16/44 (2013.01) [A61K 47/643 (2017.08); A61P 25/36 (2018.01); C07K 2317/10 (2013.01); C07K 2317/565 (2013.01); G01N 33/94 (2013.01)] 18 Claims
 
1. An antibody or antigen-binding fragment thereof which can specifically bind to naloxone and naltrexone, wherein the antibody or antigen-binding fragment is produced by immunization of a non-human animal with an antigen of Formula III:

OG Complex Work Unit Chemistry
wherein, in Formula III: A is a hetero atom selected from the group consisting of —O—, —N—, or —S—; B is a functional group selected from the group consisting of —C—, a lower alkyl (C0 to C10), —CONH—, —SO2—, or —PO4—; C is a carrier protein; and R2 is H, alkyl, allyl, or methylenecyclopropyl; and
wherein the antibody or antigen-binding fragment thereof comprises:
a heavy chain variable region CDR1 having the amino acid sequence of SEQ ID NO:2;
a heavy chain variable region CDR2 having the amino acid sequence of SEQ ID NO:3;
a heavy chain variable region CDR3 having the amino acid sequence of SEQ ID NO:4;
a light chain variable region CDR1 having the amino acid sequence of SEQ ID NO:6;
a light chain variable region CDR2 having the amino acid sequence of SEQ ID NO:7; and
a light chain variable region CDR3 having the amino acid sequence of SEQ ID NO:8.